These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29205255)

  • 1. Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer.
    Tomaszewski S; Gauthier S; Wimo A; Rosa-Neto P
    J Prev Alzheimers Dis; 2016; 3(3):164-172. PubMed ID: 29205255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives.
    Pardo-Moreno T; González-Acedo A; Rivas-Domínguez A; García-Morales V; García-Cozar FJ; Ramos-Rodríguez JJ; Melguizo-Rodríguez L
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapy for AD?
    Golde TE
    J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
    Liščić RM
    Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    Turner RS
    Semin Neurol; 2006 Nov; 26(5):499-506. PubMed ID: 17048151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
    Medina M; Avila J
    Biochem Pharmacol; 2014 Apr; 88(4):540-7. PubMed ID: 24462919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future treatments for Alzheimer's disease.
    Yiannopoulou KG; Papageorgiou SG
    Ther Adv Neurol Disord; 2013 Jan; 6(1):19-33. PubMed ID: 23277790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the pharmacological treatment of Alzheimer's disease.
    Massoud F; Gauthier S
    Curr Neuropharmacol; 2010 Mar; 8(1):69-80. PubMed ID: 20808547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival time in Alzheimer's disease: An overlooked measure of safety and efficacy of disease-modifying therapies.
    Kurkinen M; Daly T
    Adv Clin Exp Med; 2024 Oct; 33(10):1039-1043. PubMed ID: 39412276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.